{"gene":"NT5DC2","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2019,"finding":"NT5DC2 physically binds to tyrosine hydroxylase (TH) as identified by nano-LC-MS/MS analysis of immunoprecipitates from PC12D cells; siRNA-mediated knockdown of NT5DC2 increased catecholamine (dopamine, noradrenaline, adrenaline) synthesis without changing TH protein levels, indicating NT5DC2 inhibits TH catalytic activity rather than its stability.","method":"Immunoprecipitation with anti-TH antibody followed by nano-LC-MS/MS; siRNA knockdown with catecholamine synthesis measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and MS identification, functional siRNA knockdown with defined biochemical readout, single lab but two orthogonal methods","pmids":["31279527"],"is_preprint":false},{"year":2020,"finding":"NT5DC2 decreases DOPA synthesis by promoting dephosphorylation of TH at Ser40; siRNA knockdown of NT5DC2 increased TH phosphorylation at Ser residues and enhanced DOPA synthesis, and immunocytochemistry showed NT5DC2 and TH co-localize in the cytoplasm, with NT5DC2 proposed to act as a phosphatase or phosphatase-activator on TH.","method":"siRNA knockdown, Western blot for phospho-TH (Ser40), DOPA/catecholamine measurement, immunocytochemistry for co-localization","journal":"Journal of neural transmission","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (siRNA, Western blot, immunocytochemistry), single lab, functional readout tied to phosphorylation state","pmids":["32778969"],"is_preprint":false},{"year":2024,"finding":"Purified NT5DC2-tag protein binds to the phosphorylated form of recombinant human TH type 1 (rhTH1) in vitro; overexpression of NT5DC2 decreased DOPA levels; incubation of cell lysate or purified NT5DC2-tag with phosphorylated rhTH1 at 37°C decreased TH phosphorylation, demonstrating NT5DC2 promotes TH dephosphorylation acting similarly to a phosphatase.","method":"In vitro binding assay with purified recombinant proteins, Western blot for phospho-TH, DOPA measurement by overexpression, proteomic analysis by mass spectrometry","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified recombinant proteins demonstrating dephosphorylation activity, combined with cell overexpression and proteomic analysis, single lab","pmids":["38382359"],"is_preprint":false},{"year":2025,"finding":"NT5DC2 binds primarily to the non-phosphorylated form of monoamine oxidase A (MAO A); siRNA-mediated NT5DC2 downregulation reduced MAO A activity, decreased dopamine metabolism, and increased noradrenaline synthesis in PC12D cells, indicating NT5DC2 promotes MAO A activity.","method":"Affinity purification-mass spectrometry (interaction identification), Western blot for MAO A binding, siRNA knockdown with MAO A activity assay and catecholamine/metabolite measurement","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — AP-MS interaction followed by functional siRNA knockdown with enzyme activity readout, single lab, two orthogonal methods","pmids":["40751758"],"is_preprint":false},{"year":2020,"finding":"NT5DC2 directly binds EGFR (identified by co-immunoprecipitation and LC-MS/MS) and stabilizes EGFR protein by reducing its ubiquitination and preventing proteasomal degradation, thereby activating downstream EGFR signaling to promote hepatocellular carcinoma cell proliferation.","method":"Co-immunoprecipitation, LC-MS/MS, ubiquitination assay, Western blot, in vitro and in vivo proliferation assays, EGFR inhibitor (erlotinib) rescue","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP confirmed by MS, ubiquitination assay establishing mechanism, pharmacological rescue with EGFR inhibitor, multiple orthogonal methods, replicated in two cell lines","pmids":["32382041"],"is_preprint":false},{"year":2019,"finding":"NT5DC2 knockdown in glioma stem-like cells (GSCs) markedly reduces Fyn expression (a Src family kinase), inhibits tumorsphere formation and cell viability in vitro, and suppresses tumorigenesis in vivo, placing NT5DC2 upstream of Fyn in GSC maintenance.","method":"siRNA/shRNA knockdown, tumorsphere formation assay, cell viability assay, in vivo xenograft model, Western blot for Fyn","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined molecular (Fyn downregulation) and cellular phenotype readouts, in vitro and in vivo, single lab","pmids":["30978441"],"is_preprint":false},{"year":2021,"finding":"NT5DC2 interacts with unpalmitoylated TEAD4 and protects it from ubiquitin-proteasome degradation; TRIM27 is identified as the E3 ubiquitin ligase mediating K27/K48-linked ubiquitination of unpalmitoylated TEAD4 at Lys278; TEAD4 in turn transcriptionally activates NT5DC2 promoter, forming a positive feedback loop.","method":"Co-immunoprecipitation, ubiquitination assay, dual-luciferase reporter assay, shRNA knockdown, in vitro and in vivo proliferation assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, ubiquitination site mapping, luciferase assay for transcriptional feedback, single lab with multiple orthogonal methods","pmids":["33993634"],"is_preprint":false},{"year":2020,"finding":"NT5DC2 knockdown in NSCLC cells increases p53 expression and p53-dependent apoptosis and G2 arrest; p53 downregulation abrogates the anti-proliferative and pro-apoptotic effects of NT5DC2 knockdown, placing NT5DC2 upstream of p53 in NSCLC cell survival.","method":"siRNA knockdown, overexpression, flow cytometry (cell cycle, apoptosis), Western blot, epistasis by double knockdown (NT5DC2 + p53)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by double knockdown with defined phenotypic readout, single lab, multiple orthogonal methods","pmids":["32962856"],"is_preprint":false},{"year":2020,"finding":"NT5DC2 knockdown in CRC cells reduces HIF-1α and VEGF-A expression, inhibits angiogenesis (tube formation), suppresses CCL2/CCR2 expression, and blocks AKT/NF-κB signaling; VEGF reduction is necessary for the anti-proliferative, anti-migratory, and anti-angiogenic effects of NT5DC2 knockdown, defining an NT5DC2/VEGF/CCL2 axis.","method":"shRNA knockdown (lentiviral), tube formation assay, conditioned medium co-culture, Western blot, in vivo xenograft and lung metastasis model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable shRNA knockdown with multiple functional readouts and epistasis (VEGF rescue), in vitro and in vivo, single lab","pmids":["32991874"],"is_preprint":false},{"year":2024,"finding":"NT5DC2 interacts with EGFR in TNBC cells to promote downstream EGFR signal transduction; NT5DC2 knockdown suppresses glycolysis (reduced extracellular acidification rate, ATP, lactate, glucose uptake), and EGFR pathway activation counteracts the effects of NT5DC2 knockdown, confirming NT5DC2 acts via EGFR.","method":"Co-immunoprecipitation, siRNA knockdown, EGFR pathway rescue experiment, Seahorse/metabolic assays, in vivo xenograft","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, pharmacological/genetic rescue establishing pathway dependency, multiple functional readouts, single lab","pmids":["38289126"],"is_preprint":false},{"year":2022,"finding":"IGF2BP2 RNA-binding protein binds to NT5DC2 mRNA (confirmed by RNA pulldown and immunoprecipitation); IGF2BP2 upregulation reverses the anti-proliferative, pro-apoptotic, and cell-cycle arrest effects of NT5DC2 knockdown in DLBCL cells, demonstrating IGF2BP2 acts upstream of NT5DC2 to regulate its expression post-transcriptionally.","method":"RNA pulldown assay, RNA immunoprecipitation, siRNA/shRNA knockdown, overexpression, flow cytometry, Western blot","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA pulldown and RIP confirming direct binding, epistasis rescue experiment, single lab with multiple orthogonal methods","pmids":["35894142"],"is_preprint":false},{"year":2024,"finding":"DDX3X RNA helicase binds NT5DC2 mRNA and promotes its translation in CML cells; DDX3X inhibition reduces NT5DC2 protein and eliminates leukemia stem cells, with NT5DC2 acting as a functional mediator downstream of DDX3X in CML LSC maintenance.","method":"RNA immunoprecipitation (DDX3X binds NT5DC2 mRNA), shRNA knockdown of DDX3X with NT5DC2 protein measurement, epistasis rescue with NT5DC2 overexpression, CML mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP for mRNA binding, genetic epistasis in mouse model, single lab with multiple orthogonal methods","pmids":["39516658"],"is_preprint":false},{"year":2024,"finding":"CTCF transcriptionally activates NT5DC2 in lung squamous cell carcinoma cells; IGF2BP3 stabilizes CTCF mRNA via m6A methylation, forming an IGF2BP3/CTCF/NT5DC2 regulatory axis; NT5DC2 knockdown inhibits LUSC cell proliferation, glycolysis, and M2 macrophage polarization, and these effects are rescued by NT5DC2 overexpression.","method":"Dual-luciferase reporter assay (CTCF→NT5DC2 promoter), RNA immunoprecipitation, m6A RIP assay, siRNA knockdown, flow cytometry, xenograft model","journal":"The clinical respiratory journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase assay and RIP for upstream regulation, functional epistasis rescue, single lab with multiple orthogonal methods","pmids":["39506204"],"is_preprint":false},{"year":2026,"finding":"NT5DC2 physically interacts with ACSL3 (a ferroptosis suppressor protein) and inhibits its ubiquitination, thereby stabilizing ACSL3 protein; NT5DC2 knockdown promotes ferroptosis in bladder cancer cells, and this effect is rescued by ACSL3; NT5DC2 also mediates oleic acid-induced upregulation of ACSL3.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ferroptosis assay, rescue experiment with ACSL3 overexpression, in vivo xenograft","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, ubiquitination assay establishing mechanism, epistasis rescue, single lab with multiple orthogonal methods","pmids":["41974665"],"is_preprint":false}],"current_model":"NT5DC2 is a HAD-type phosphatase-domain protein that promotes cell survival and proliferation through multiple mechanisms: it directly binds and stabilizes EGFR by blocking its ubiquitin-proteasome degradation (activating downstream EGFR signaling); it dephosphorylates tyrosine hydroxylase (TH) at Ser40 to suppress catecholamine synthesis; it binds MAO A (preferentially non-phosphorylated) to promote its activity; it stabilizes ACSL3 and TEAD4 from ubiquitin-mediated degradation; it acts upstream of Fyn kinase in glioma stem cells and upstream of p53 in NSCLC; and its translation is regulated by the DDX3X helicase and IGF2BP2/IGF2BP3 RNA-binding proteins, while its transcription is activated by CTCF."},"narrative":{"mechanistic_narrative":"NT5DC2 is a cytoplasmic HAD-phosphatase-domain protein that functions both as a regulator of catecholamine-metabolizing enzymes and as a pro-survival, pro-proliferative factor in multiple cancers by stabilizing client proteins against ubiquitin-proteasome degradation [PMID:38382359, PMID:32382041]. In catecholaminergic cells, NT5DC2 binds tyrosine hydroxylase and acts as (or recruits) a phosphatase that dephosphorylates TH at Ser40, suppressing DOPA and catecholamine synthesis; purified NT5DC2 binds phosphorylated recombinant TH and promotes its dephosphorylation in vitro, while it preferentially associates with non-phosphorylated MAO A to enhance MAO A activity and dopamine metabolism [PMID:31279527, PMID:32778969, PMID:38382359, PMID:40751758]. In tumor cells, NT5DC2 directly binds EGFR and reduces its ubiquitination to prevent proteasomal degradation, sustaining downstream EGFR signaling and glycolytic metabolism in hepatocellular carcinoma and triple-negative breast cancer [PMID:32382041, PMID:38289126]. This stabilization role extends to additional clients: NT5DC2 protects unpalmitoylated TEAD4 from TRIM27-mediated ubiquitination (with TEAD4 reciprocally activating the NT5DC2 promoter in a feedback loop) and stabilizes the ferroptosis suppressor ACSL3 by inhibiting its ubiquitination, thereby restraining ferroptosis [PMID:33993634, PMID:41974665]. Through these activities NT5DC2 supports proliferation and survival across cancer types, acting upstream of Fyn in glioma stem-like cells, upstream of p53-dependent apoptosis and G2 arrest in NSCLC, and within a HIF-1α/VEGF-A/CCL2 angiogenic axis in colorectal cancer [PMID:30978441, PMID:32962856, PMID:32991874]. NT5DC2 expression is itself controlled post-transcriptionally and transcriptionally: the RNA-binding protein IGF2BP2 and the helicase DDX3X bind NT5DC2 mRNA to promote its expression/translation in DLBCL and CML, and CTCF (stabilized via IGF2BP3/m6A) transcriptionally activates NT5DC2 in lung squamous cell carcinoma [PMID:35894142, PMID:39516658, PMID:39506204].","teleology":[{"year":2019,"claim":"Establishing the first molecular partner of NT5DC2 showed it physically engages tyrosine hydroxylase and negatively regulates catecholamine output without altering TH abundance, implying a catalytic rather than stabilizing effect.","evidence":"Anti-TH immunoprecipitation with nano-LC-MS/MS and siRNA knockdown with catecholamine measurement in PC12D cells","pmids":["31279527"],"confidence":"Medium","gaps":["Direct enzymatic mechanism on TH not yet demonstrated","Phosphorylation site not yet defined","Single cell type"]},{"year":2020,"claim":"Mapping NT5DC2's effect to TH Ser40 dephosphorylation defined the regulatory readout linking NT5DC2 to DOPA synthesis control.","evidence":"siRNA knockdown, phospho-Ser40 Western blot, DOPA measurement and immunocytochemistry co-localization","pmids":["32778969"],"confidence":"Medium","gaps":["Whether NT5DC2 is the catalytic phosphatase or an activator unresolved","No in vitro reconstitution at this stage"]},{"year":2020,"claim":"Identifying EGFR as a direct binding partner that NT5DC2 stabilizes against ubiquitin-proteasome degradation established its first oncogenic stabilization mechanism and a pharmacologically testable pathway.","evidence":"Co-IP/LC-MS/MS, ubiquitination assay, erlotinib rescue, and proliferation assays in hepatocellular carcinoma","pmids":["32382041"],"confidence":"High","gaps":["Whether stabilization requires phosphatase activity unknown","Direct binding interface not mapped"]},{"year":2020,"claim":"Placing NT5DC2 upstream of p53 and within a HIF-1α/VEGF-A/CCL2 axis extended its pro-survival role to apoptosis suppression and angiogenesis in additional cancers.","evidence":"siRNA/shRNA knockdown with epistasis (NT5DC2+p53; VEGF rescue), flow cytometry, tube formation, and xenograft models in NSCLC and CRC","pmids":["32962856","32991874"],"confidence":"Medium","gaps":["Direct molecular link between NT5DC2 and p53 or HIF-1α not defined","Mechanism may be indirect via EGFR"]},{"year":2019,"claim":"Demonstrating that NT5DC2 knockdown reduces Fyn and impairs glioma stem-cell maintenance positioned NT5DC2 as a stemness regulator upstream of a Src-family kinase.","evidence":"siRNA/shRNA knockdown, tumorsphere and viability assays, xenograft, Fyn Western blot in glioma stem-like cells","pmids":["30978441"],"confidence":"Medium","gaps":["Whether Fyn regulation is direct or transcriptional unknown","No physical interaction shown"]},{"year":2021,"claim":"Showing NT5DC2 shields unpalmitoylated TEAD4 from TRIM27-mediated ubiquitination, with TEAD4 reactivating the NT5DC2 promoter, revealed a self-reinforcing stabilization circuit.","evidence":"Co-IP, ubiquitination site mapping (Lys278), dual-luciferase reporter, and proliferation assays","pmids":["33993634"],"confidence":"Medium","gaps":["Whether NT5DC2 competes directly with TRIM27 unknown","Role of NT5DC2 phosphatase activity in protection untested"]},{"year":2022,"claim":"Identifying IGF2BP2 as an RNA-binding regulator of NT5DC2 mRNA established post-transcriptional control of NT5DC2 levels driving the survival phenotype.","evidence":"RNA pulldown, RIP, knockdown/overexpression epistasis, flow cytometry in DLBCL","pmids":["35894142"],"confidence":"Medium","gaps":["m6A dependence of IGF2BP2 binding not tested here","Effect on translation vs stability not separated"]},{"year":2024,"claim":"In vitro reconstitution with purified proteins demonstrated that NT5DC2 binds phosphorylated TH and directly promotes its dephosphorylation, advancing the model from correlation to a phosphatase-like activity.","evidence":"In vitro binding and dephosphorylation assays with purified recombinant NT5DC2 and rhTH1, overexpression DOPA measurement","pmids":["38382359"],"confidence":"High","gaps":["Whether NT5DC2 itself is catalytic or an obligate cofactor still not fully resolved","Active-site residues not mutated"]},{"year":2024,"claim":"Extending the EGFR-stabilization mechanism to TNBC and linking it to glycolytic metabolism generalized NT5DC2's role in EGFR-driven tumor metabolism.","evidence":"Co-IP, siRNA knockdown with EGFR-pathway rescue, Seahorse metabolic assays, xenograft in TNBC","pmids":["38289126"],"confidence":"Medium","gaps":["Direct binding interface unmapped","Metabolic effect may be entirely downstream of EGFR"]},{"year":2024,"claim":"Defining DDX3X-driven translation and CTCF-driven transcription (via IGF2BP3/m6A) of NT5DC2 placed it within layered upstream regulatory axes governing leukemia stem cells and lung squamous carcinoma.","evidence":"RIP, shRNA knockdown with epistasis rescue (CML model); dual-luciferase, m6A RIP, knockdown/xenograft (LUSC)","pmids":["39516658","39506204"],"confidence":"Medium","gaps":["Whether these regulators are tissue-specific or general unknown","Direct vs indirect regulation of NT5DC2 not fully separated"]},{"year":2025,"claim":"Identifying preferential binding to non-phosphorylated MAO A and enhancement of its activity broadened NT5DC2's role in monoamine metabolism beyond TH.","evidence":"AP-MS, MAO A binding Western blot, siRNA knockdown with MAO A activity and metabolite assays in PC12D cells","pmids":["40751758"],"confidence":"Medium","gaps":["Mechanism by which NT5DC2 enhances MAO A activity undefined","Phosphorylation-state dependence of binding not mechanistically explained"]},{"year":2026,"claim":"Showing NT5DC2 stabilizes ACSL3 by inhibiting its ubiquitination and restrains ferroptosis added a lipid-metabolism/cell-death dimension to its stabilization function.","evidence":"Co-IP, ubiquitination assay, ferroptosis assays, ACSL3 rescue, oleic acid stimulation, xenograft in bladder cancer","pmids":["41974665"],"confidence":"Medium","gaps":["Responsible E3 ligase not identified","Whether stabilization needs phosphatase activity untested"]},{"year":null,"claim":"Whether NT5DC2's HAD phosphatase activity is the unifying biochemical mechanism behind both its TH/MAO A regulation and its many ubiquitination-blocking stabilization roles remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No catalytic-dead mutant tested across its client proteins","No structural model of substrate engagement","Connection between catecholamine and cancer functions unestablished"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[4,6,13]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,3,9]}],"complexes":[],"partners":["TH","MAOA","EGFR","TEAD4","ACSL3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H857","full_name":"5'-nucleotidase domain-containing protein 2","aliases":[],"length_aa":520,"mass_kda":60.7,"function":"Promotes dephosphorylation of tyrosine 3-monooxygenase TH which decreases TH catalytic activity and leads to reduced synthesis of catecholamines including dopamine, noradrenaline and adrenaline. The exact mechanism of activity is unknown but may act as a phosphatase or promote the activity of phosphatases or may inhibit phosphorylation by acting as a barrier to interfere with protein kinase access","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9H857/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NT5DC2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NT5DC2","total_profiled":1310},"omim":[{"mim_id":"621077","title":"5-PRIME-@NUCLEOTIDASE DOMAIN-CONTAINING PROTEIN 2; NT5DC2","url":"https://www.omim.org/entry/621077"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NT5DC2"},"hgnc":{"alias_symbol":["FLJ12442"],"prev_symbol":[]},"alphafold":{"accession":"Q9H857","domains":[{"cath_id":"3.40.50.1000","chopping":"63-82_240-381","consensus_level":"medium","plddt":93.8638,"start":63,"end":381},{"cath_id":"-","chopping":"85-238","consensus_level":"medium","plddt":94.1929,"start":85,"end":238}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H857","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H857-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H857-F1-predicted_aligned_error_v6.png","plddt_mean":86.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NT5DC2","jax_strain_url":"https://www.jax.org/strain/search?query=NT5DC2"},"sequence":{"accession":"Q9H857","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H857.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H857/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H857"}},"corpus_meta":[{"pmid":"32382041","id":"PMC_32382041","title":"NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32382041","citation_count":57,"is_preprint":false},{"pmid":"30978441","id":"PMC_30978441","title":"NT5DC2 promotes tumorigenicity of glioma stem-like cells by upregulating fyn.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30978441","citation_count":40,"is_preprint":false},{"pmid":"32991874","id":"PMC_32991874","title":"NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32991874","citation_count":26,"is_preprint":false},{"pmid":"32962856","id":"PMC_32962856","title":"NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32962856","citation_count":20,"is_preprint":false},{"pmid":"33993634","id":"PMC_33993634","title":"NT5DC2 promotes leiomyosarcoma tumour cell growth via stabilizing unpalmitoylated TEAD4 and generating a positive feedback loop.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33993634","citation_count":18,"is_preprint":false},{"pmid":"31279527","id":"PMC_31279527","title":"Identification by nano-LC-MS/MS of NT5DC2 as a protein binding to tyrosine hydroxylase: Down-regulation of NT5DC2 by siRNA increases catecholamine synthesis in PC12D cells.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31279527","citation_count":17,"is_preprint":false},{"pmid":"35894142","id":"PMC_35894142","title":"Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/35894142","citation_count":10,"is_preprint":false},{"pmid":"32778969","id":"PMC_32778969","title":"NT5DC2 affects the phosphorylation of tyrosine hydroxylase regulating its catalytic activity.","date":"2020","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/32778969","citation_count":10,"is_preprint":false},{"pmid":"38289126","id":"PMC_38289126","title":"NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38289126","citation_count":7,"is_preprint":false},{"pmid":"38382359","id":"PMC_38382359","title":"Role of NT5DC2 in tyrosine hydroxylase phosphorylation based on the analysis of NT5DC2-binding proteins.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38382359","citation_count":5,"is_preprint":false},{"pmid":"39516658","id":"PMC_39516658","title":"Targeting DDX3X eliminates leukemia stem cells in chronic myeloid leukemia by blocking NT5DC2 mRNA translation.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39516658","citation_count":5,"is_preprint":false},{"pmid":"36799157","id":"PMC_36799157","title":"[Corrigendum] Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway.","date":"2023","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/36799157","citation_count":2,"is_preprint":false},{"pmid":"39506204","id":"PMC_39506204","title":"IGF2BP3/CTCF Axis-Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas.","date":"2024","source":"The clinical respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/39506204","citation_count":2,"is_preprint":false},{"pmid":"39165948","id":"PMC_39165948","title":"Quantitative proteomics and immunohistochemistry uncover NT5DC2 as a diagnostic biomarker for papillary urothelial carcinoma.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39165948","citation_count":0,"is_preprint":false},{"pmid":"40751758","id":"PMC_40751758","title":"NT5DC2 downregulation suppresses monoamine oxidase activity and promotes catecholamine synthesis in PC12D cells.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40751758","citation_count":0,"is_preprint":false},{"pmid":"40302808","id":"PMC_40302808","title":"circ_0046599 Promotes HCC Progression by Competing with miR-1322 to Enhance NT5DC2 Expression.","date":"2025","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40302808","citation_count":0,"is_preprint":false},{"pmid":"41974665","id":"PMC_41974665","title":"NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/41974665","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.07.651779","title":"NT5DC2 downregulation suppresses monoamine oxidase activity and increases catecholamine levels in PC12D cells","date":"2025-05-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.07.651779","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.02.25337157","title":"Human Kidney Alternative Splicing Information Illuminates Cardiovascular-Kidney-Metabolic Syndrome Risk","date":"2025-10-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.02.25337157","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12808,"output_tokens":3783,"usd":0.047585,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11646,"output_tokens":4141,"usd":0.080878,"stage2_stop_reason":"end_turn"},"total_usd":0.128463,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"NT5DC2 physically binds to tyrosine hydroxylase (TH) as identified by nano-LC-MS/MS analysis of immunoprecipitates from PC12D cells; siRNA-mediated knockdown of NT5DC2 increased catecholamine (dopamine, noradrenaline, adrenaline) synthesis without changing TH protein levels, indicating NT5DC2 inhibits TH catalytic activity rather than its stability.\",\n      \"method\": \"Immunoprecipitation with anti-TH antibody followed by nano-LC-MS/MS; siRNA knockdown with catecholamine synthesis measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and MS identification, functional siRNA knockdown with defined biochemical readout, single lab but two orthogonal methods\",\n      \"pmids\": [\"31279527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NT5DC2 decreases DOPA synthesis by promoting dephosphorylation of TH at Ser40; siRNA knockdown of NT5DC2 increased TH phosphorylation at Ser residues and enhanced DOPA synthesis, and immunocytochemistry showed NT5DC2 and TH co-localize in the cytoplasm, with NT5DC2 proposed to act as a phosphatase or phosphatase-activator on TH.\",\n      \"method\": \"siRNA knockdown, Western blot for phospho-TH (Ser40), DOPA/catecholamine measurement, immunocytochemistry for co-localization\",\n      \"journal\": \"Journal of neural transmission\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (siRNA, Western blot, immunocytochemistry), single lab, functional readout tied to phosphorylation state\",\n      \"pmids\": [\"32778969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Purified NT5DC2-tag protein binds to the phosphorylated form of recombinant human TH type 1 (rhTH1) in vitro; overexpression of NT5DC2 decreased DOPA levels; incubation of cell lysate or purified NT5DC2-tag with phosphorylated rhTH1 at 37°C decreased TH phosphorylation, demonstrating NT5DC2 promotes TH dephosphorylation acting similarly to a phosphatase.\",\n      \"method\": \"In vitro binding assay with purified recombinant proteins, Western blot for phospho-TH, DOPA measurement by overexpression, proteomic analysis by mass spectrometry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified recombinant proteins demonstrating dephosphorylation activity, combined with cell overexpression and proteomic analysis, single lab\",\n      \"pmids\": [\"38382359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NT5DC2 binds primarily to the non-phosphorylated form of monoamine oxidase A (MAO A); siRNA-mediated NT5DC2 downregulation reduced MAO A activity, decreased dopamine metabolism, and increased noradrenaline synthesis in PC12D cells, indicating NT5DC2 promotes MAO A activity.\",\n      \"method\": \"Affinity purification-mass spectrometry (interaction identification), Western blot for MAO A binding, siRNA knockdown with MAO A activity assay and catecholamine/metabolite measurement\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — AP-MS interaction followed by functional siRNA knockdown with enzyme activity readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"40751758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NT5DC2 directly binds EGFR (identified by co-immunoprecipitation and LC-MS/MS) and stabilizes EGFR protein by reducing its ubiquitination and preventing proteasomal degradation, thereby activating downstream EGFR signaling to promote hepatocellular carcinoma cell proliferation.\",\n      \"method\": \"Co-immunoprecipitation, LC-MS/MS, ubiquitination assay, Western blot, in vitro and in vivo proliferation assays, EGFR inhibitor (erlotinib) rescue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP confirmed by MS, ubiquitination assay establishing mechanism, pharmacological rescue with EGFR inhibitor, multiple orthogonal methods, replicated in two cell lines\",\n      \"pmids\": [\"32382041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NT5DC2 knockdown in glioma stem-like cells (GSCs) markedly reduces Fyn expression (a Src family kinase), inhibits tumorsphere formation and cell viability in vitro, and suppresses tumorigenesis in vivo, placing NT5DC2 upstream of Fyn in GSC maintenance.\",\n      \"method\": \"siRNA/shRNA knockdown, tumorsphere formation assay, cell viability assay, in vivo xenograft model, Western blot for Fyn\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined molecular (Fyn downregulation) and cellular phenotype readouts, in vitro and in vivo, single lab\",\n      \"pmids\": [\"30978441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NT5DC2 interacts with unpalmitoylated TEAD4 and protects it from ubiquitin-proteasome degradation; TRIM27 is identified as the E3 ubiquitin ligase mediating K27/K48-linked ubiquitination of unpalmitoylated TEAD4 at Lys278; TEAD4 in turn transcriptionally activates NT5DC2 promoter, forming a positive feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, dual-luciferase reporter assay, shRNA knockdown, in vitro and in vivo proliferation assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, ubiquitination site mapping, luciferase assay for transcriptional feedback, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33993634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NT5DC2 knockdown in NSCLC cells increases p53 expression and p53-dependent apoptosis and G2 arrest; p53 downregulation abrogates the anti-proliferative and pro-apoptotic effects of NT5DC2 knockdown, placing NT5DC2 upstream of p53 in NSCLC cell survival.\",\n      \"method\": \"siRNA knockdown, overexpression, flow cytometry (cell cycle, apoptosis), Western blot, epistasis by double knockdown (NT5DC2 + p53)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by double knockdown with defined phenotypic readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32962856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NT5DC2 knockdown in CRC cells reduces HIF-1α and VEGF-A expression, inhibits angiogenesis (tube formation), suppresses CCL2/CCR2 expression, and blocks AKT/NF-κB signaling; VEGF reduction is necessary for the anti-proliferative, anti-migratory, and anti-angiogenic effects of NT5DC2 knockdown, defining an NT5DC2/VEGF/CCL2 axis.\",\n      \"method\": \"shRNA knockdown (lentiviral), tube formation assay, conditioned medium co-culture, Western blot, in vivo xenograft and lung metastasis model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable shRNA knockdown with multiple functional readouts and epistasis (VEGF rescue), in vitro and in vivo, single lab\",\n      \"pmids\": [\"32991874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NT5DC2 interacts with EGFR in TNBC cells to promote downstream EGFR signal transduction; NT5DC2 knockdown suppresses glycolysis (reduced extracellular acidification rate, ATP, lactate, glucose uptake), and EGFR pathway activation counteracts the effects of NT5DC2 knockdown, confirming NT5DC2 acts via EGFR.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, EGFR pathway rescue experiment, Seahorse/metabolic assays, in vivo xenograft\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, pharmacological/genetic rescue establishing pathway dependency, multiple functional readouts, single lab\",\n      \"pmids\": [\"38289126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IGF2BP2 RNA-binding protein binds to NT5DC2 mRNA (confirmed by RNA pulldown and immunoprecipitation); IGF2BP2 upregulation reverses the anti-proliferative, pro-apoptotic, and cell-cycle arrest effects of NT5DC2 knockdown in DLBCL cells, demonstrating IGF2BP2 acts upstream of NT5DC2 to regulate its expression post-transcriptionally.\",\n      \"method\": \"RNA pulldown assay, RNA immunoprecipitation, siRNA/shRNA knockdown, overexpression, flow cytometry, Western blot\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA pulldown and RIP confirming direct binding, epistasis rescue experiment, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35894142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DDX3X RNA helicase binds NT5DC2 mRNA and promotes its translation in CML cells; DDX3X inhibition reduces NT5DC2 protein and eliminates leukemia stem cells, with NT5DC2 acting as a functional mediator downstream of DDX3X in CML LSC maintenance.\",\n      \"method\": \"RNA immunoprecipitation (DDX3X binds NT5DC2 mRNA), shRNA knockdown of DDX3X with NT5DC2 protein measurement, epistasis rescue with NT5DC2 overexpression, CML mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP for mRNA binding, genetic epistasis in mouse model, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39516658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CTCF transcriptionally activates NT5DC2 in lung squamous cell carcinoma cells; IGF2BP3 stabilizes CTCF mRNA via m6A methylation, forming an IGF2BP3/CTCF/NT5DC2 regulatory axis; NT5DC2 knockdown inhibits LUSC cell proliferation, glycolysis, and M2 macrophage polarization, and these effects are rescued by NT5DC2 overexpression.\",\n      \"method\": \"Dual-luciferase reporter assay (CTCF→NT5DC2 promoter), RNA immunoprecipitation, m6A RIP assay, siRNA knockdown, flow cytometry, xenograft model\",\n      \"journal\": \"The clinical respiratory journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase assay and RIP for upstream regulation, functional epistasis rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39506204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"NT5DC2 physically interacts with ACSL3 (a ferroptosis suppressor protein) and inhibits its ubiquitination, thereby stabilizing ACSL3 protein; NT5DC2 knockdown promotes ferroptosis in bladder cancer cells, and this effect is rescued by ACSL3; NT5DC2 also mediates oleic acid-induced upregulation of ACSL3.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, ferroptosis assay, rescue experiment with ACSL3 overexpression, in vivo xenograft\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, ubiquitination assay establishing mechanism, epistasis rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"41974665\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NT5DC2 is a HAD-type phosphatase-domain protein that promotes cell survival and proliferation through multiple mechanisms: it directly binds and stabilizes EGFR by blocking its ubiquitin-proteasome degradation (activating downstream EGFR signaling); it dephosphorylates tyrosine hydroxylase (TH) at Ser40 to suppress catecholamine synthesis; it binds MAO A (preferentially non-phosphorylated) to promote its activity; it stabilizes ACSL3 and TEAD4 from ubiquitin-mediated degradation; it acts upstream of Fyn kinase in glioma stem cells and upstream of p53 in NSCLC; and its translation is regulated by the DDX3X helicase and IGF2BP2/IGF2BP3 RNA-binding proteins, while its transcription is activated by CTCF.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NT5DC2 is a cytoplasmic HAD-phosphatase-domain protein that functions both as a regulator of catecholamine-metabolizing enzymes and as a pro-survival, pro-proliferative factor in multiple cancers by stabilizing client proteins against ubiquitin-proteasome degradation [#2, #4]. In catecholaminergic cells, NT5DC2 binds tyrosine hydroxylase and acts as (or recruits) a phosphatase that dephosphorylates TH at Ser40, suppressing DOPA and catecholamine synthesis; purified NT5DC2 binds phosphorylated recombinant TH and promotes its dephosphorylation in vitro, while it preferentially associates with non-phosphorylated MAO A to enhance MAO A activity and dopamine metabolism [#0, #1, #2, #3]. In tumor cells, NT5DC2 directly binds EGFR and reduces its ubiquitination to prevent proteasomal degradation, sustaining downstream EGFR signaling and glycolytic metabolism in hepatocellular carcinoma and triple-negative breast cancer [#4, #9]. This stabilization role extends to additional clients: NT5DC2 protects unpalmitoylated TEAD4 from TRIM27-mediated ubiquitination (with TEAD4 reciprocally activating the NT5DC2 promoter in a feedback loop) and stabilizes the ferroptosis suppressor ACSL3 by inhibiting its ubiquitination, thereby restraining ferroptosis [#6, #13]. Through these activities NT5DC2 supports proliferation and survival across cancer types, acting upstream of Fyn in glioma stem-like cells, upstream of p53-dependent apoptosis and G2 arrest in NSCLC, and within a HIF-1\\u03b1/VEGF-A/CCL2 angiogenic axis in colorectal cancer [#5, #7, #8]. NT5DC2 expression is itself controlled post-transcriptionally and transcriptionally: the RNA-binding protein IGF2BP2 and the helicase DDX3X bind NT5DC2 mRNA to promote its expression/translation in DLBCL and CML, and CTCF (stabilized via IGF2BP3/m6A) transcriptionally activates NT5DC2 in lung squamous cell carcinoma [#10, #11, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing the first molecular partner of NT5DC2 showed it physically engages tyrosine hydroxylase and negatively regulates catecholamine output without altering TH abundance, implying a catalytic rather than stabilizing effect.\",\n      \"evidence\": \"Anti-TH immunoprecipitation with nano-LC-MS/MS and siRNA knockdown with catecholamine measurement in PC12D cells\",\n      \"pmids\": [\"31279527\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic mechanism on TH not yet demonstrated\", \"Phosphorylation site not yet defined\", \"Single cell type\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mapping NT5DC2's effect to TH Ser40 dephosphorylation defined the regulatory readout linking NT5DC2 to DOPA synthesis control.\",\n      \"evidence\": \"siRNA knockdown, phospho-Ser40 Western blot, DOPA measurement and immunocytochemistry co-localization\",\n      \"pmids\": [\"32778969\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NT5DC2 is the catalytic phosphatase or an activator unresolved\", \"No in vitro reconstitution at this stage\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying EGFR as a direct binding partner that NT5DC2 stabilizes against ubiquitin-proteasome degradation established its first oncogenic stabilization mechanism and a pharmacologically testable pathway.\",\n      \"evidence\": \"Co-IP/LC-MS/MS, ubiquitination assay, erlotinib rescue, and proliferation assays in hepatocellular carcinoma\",\n      \"pmids\": [\"32382041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether stabilization requires phosphatase activity unknown\", \"Direct binding interface not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing NT5DC2 upstream of p53 and within a HIF-1\\u03b1/VEGF-A/CCL2 axis extended its pro-survival role to apoptosis suppression and angiogenesis in additional cancers.\",\n      \"evidence\": \"siRNA/shRNA knockdown with epistasis (NT5DC2+p53; VEGF rescue), flow cytometry, tube formation, and xenograft models in NSCLC and CRC\",\n      \"pmids\": [\"32962856\", \"32991874\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between NT5DC2 and p53 or HIF-1\\u03b1 not defined\", \"Mechanism may be indirect via EGFR\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that NT5DC2 knockdown reduces Fyn and impairs glioma stem-cell maintenance positioned NT5DC2 as a stemness regulator upstream of a Src-family kinase.\",\n      \"evidence\": \"siRNA/shRNA knockdown, tumorsphere and viability assays, xenograft, Fyn Western blot in glioma stem-like cells\",\n      \"pmids\": [\"30978441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Fyn regulation is direct or transcriptional unknown\", \"No physical interaction shown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing NT5DC2 shields unpalmitoylated TEAD4 from TRIM27-mediated ubiquitination, with TEAD4 reactivating the NT5DC2 promoter, revealed a self-reinforcing stabilization circuit.\",\n      \"evidence\": \"Co-IP, ubiquitination site mapping (Lys278), dual-luciferase reporter, and proliferation assays\",\n      \"pmids\": [\"33993634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NT5DC2 competes directly with TRIM27 unknown\", \"Role of NT5DC2 phosphatase activity in protection untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying IGF2BP2 as an RNA-binding regulator of NT5DC2 mRNA established post-transcriptional control of NT5DC2 levels driving the survival phenotype.\",\n      \"evidence\": \"RNA pulldown, RIP, knockdown/overexpression epistasis, flow cytometry in DLBCL\",\n      \"pmids\": [\"35894142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A dependence of IGF2BP2 binding not tested here\", \"Effect on translation vs stability not separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"In vitro reconstitution with purified proteins demonstrated that NT5DC2 binds phosphorylated TH and directly promotes its dephosphorylation, advancing the model from correlation to a phosphatase-like activity.\",\n      \"evidence\": \"In vitro binding and dephosphorylation assays with purified recombinant NT5DC2 and rhTH1, overexpression DOPA measurement\",\n      \"pmids\": [\"38382359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NT5DC2 itself is catalytic or an obligate cofactor still not fully resolved\", \"Active-site residues not mutated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extending the EGFR-stabilization mechanism to TNBC and linking it to glycolytic metabolism generalized NT5DC2's role in EGFR-driven tumor metabolism.\",\n      \"evidence\": \"Co-IP, siRNA knockdown with EGFR-pathway rescue, Seahorse metabolic assays, xenograft in TNBC\",\n      \"pmids\": [\"38289126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface unmapped\", \"Metabolic effect may be entirely downstream of EGFR\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining DDX3X-driven translation and CTCF-driven transcription (via IGF2BP3/m6A) of NT5DC2 placed it within layered upstream regulatory axes governing leukemia stem cells and lung squamous carcinoma.\",\n      \"evidence\": \"RIP, shRNA knockdown with epistasis rescue (CML model); dual-luciferase, m6A RIP, knockdown/xenograft (LUSC)\",\n      \"pmids\": [\"39516658\", \"39506204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these regulators are tissue-specific or general unknown\", \"Direct vs indirect regulation of NT5DC2 not fully separated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying preferential binding to non-phosphorylated MAO A and enhancement of its activity broadened NT5DC2's role in monoamine metabolism beyond TH.\",\n      \"evidence\": \"AP-MS, MAO A binding Western blot, siRNA knockdown with MAO A activity and metabolite assays in PC12D cells\",\n      \"pmids\": [\"40751758\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which NT5DC2 enhances MAO A activity undefined\", \"Phosphorylation-state dependence of binding not mechanistically explained\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showing NT5DC2 stabilizes ACSL3 by inhibiting its ubiquitination and restrains ferroptosis added a lipid-metabolism/cell-death dimension to its stabilization function.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, ferroptosis assays, ACSL3 rescue, oleic acid stimulation, xenograft in bladder cancer\",\n      \"pmids\": [\"41974665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Responsible E3 ligase not identified\", \"Whether stabilization needs phosphatase activity untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether NT5DC2's HAD phosphatase activity is the unifying biochemical mechanism behind both its TH/MAO A regulation and its many ubiquitination-blocking stabilization roles remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic-dead mutant tested across its client proteins\", \"No structural model of substrate engagement\", \"Connection between catecholamine and cancer functions unestablished\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [4, 6, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TH\", \"MAOA\", \"EGFR\", \"TEAD4\", \"ACSL3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}